7. Metabolism of apolipoprotein B-100-containing lipoproteins in dyslipidaemias8. Sex-specific aspects of dyslipidaemia and atherosclerosis; Part III: Prevention and treatment strategies; 9. New clinical trials oflipid-regulating agents; 10. Genetics of dyslipidaemia andcoronary risk (personalized lipid-lowering treatment); 11. Application of proteomic, metabolomic and lipidomic approaches to coronary heart disease risk prediction; 12. N.
Lipid disorders are highly heterogeneous and widely prevalent throughout the world. Dyslipidemia is an important risk factor for atherosclerotic disease and its clinical sequelae, including myocardial infarction, ischemic stroke, and death. The impact of dyslipidemia treatment on risk for cardiovascular disease is one of the most intensively studied issues in all of medicine. This volume is an innovative approach to the identification and management of lipid disorders. Organized as a series of questions, each chapter presents a detailed yet accessible discussion of the problems posed. The ques.